Katherine Stueland - 29 Jan 2026 Form 4 Insider Report for GeneDx Holdings Corp. (WGS)

Signature
/s/ Bridget Brown, Attorney-in-Fact
Issuer symbol
WGS
Transactions as of
29 Jan 2026
Net transactions value
-$155,375
Form type
4
Filing time
02 Feb 2026, 16:30:35 UTC
Previous filing
18 Dec 2025
Next filing
05 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Stueland Katherine CHIEF EXECUTIVE OFFICER, Director C/O GENEDX HOLDINGS CORP., 333 LUDLOW ST., NORTH TOWER, 6TH FLOOR, STAMFORD /s/ Bridget Brown, Attorney-in-Fact 02 Feb 2026 0001689575

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WGS Class A Common Stock Options Exercise $0 +3,874 +27% $0.000000 18,111 29 Jan 2026 Direct F1
transaction WGS Class A Common Stock Sale $155,375 -1,653 -9.1% $94.00 16,458 29 Jan 2026 Direct F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WGS Restricted Stock Unit Options Exercise $0 -3,874 -50% $0.000000 3,874 29 Jan 2026 Class A Common Stock 3,874 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.53 to $94.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 16,458 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned RSUs representing contingent rights to receive up to an aggregate of 411,494 shares of Class A Common Stock and options to purchase up to an aggregate of 107,610 shares of Class A Common Stock, which RSUs and options vest according to their respective terms.
F5 25% of the total award vested on each of April 29, 2023 and April 29, 2024, and an additional 6.25% of the total award vested or vests thereafter on each quarterly anniversary, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the last tranche scheduled to vest on April 29, 2026. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.